The World Health Organization released preliminary results on the effectiveness of four COVID-19 treatments, and they were lackluster at best. The 11,000-person trial focused on the use of Remdesivir, Hydroxychloroquine, Lopinavir (fixed-dose combination with Ritonavir), and Interferon-β1a among patients with COVID-19 in 400 hospitals across the world. None of the treatments reduced mortality, decreased the need for breathing assistance, or shortened the length of hospital stay.
A preprint of results was released on October 15, with the final data scheduled for publication in The New England Journal of Medicine. Read more here.
Kristen Pratt Machado is executive editor for Dimensions of Dental Hygiene and Decisions in Dentistry and director of publishing operations for Belmont Publications, Inc. She has been with Belmont Publications since its inception in 2002.